Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

1.0K
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
1.0K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

921
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
921
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1000
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1000
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

388
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
388

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A National Survey of Pharmacy Skills Laboratory Faculty Perceptions of Evaluation, Promotion, and Workload Policies.

American journal of pharmaceutical education·2026
Same author

Prevalence of Student Pharmacists with Neurodivergent Conditions in a School of Pharmacy.

American journal of pharmaceutical education·2026
Same author

A Deimplementation Framework for Curricular Hoarding in Pharmacy Education.

American journal of pharmaceutical education·2026
Same author

Consensus expert recommendations for management of dysphagia during hospital admission in Parkinson's disease.

Journal of Parkinson's disease·2026
Same author

Artificial intelligence (AI) usage on advanced pharmacy practice experiences.

Currents in pharmacy teaching & learning·2025
Same author

Assessing the Acceptability of the Minnesota Effective Medication Self-Management Toolkit Four-Step Approach in Low-Income Community-Dwelling Older Adults.

The Senior care pharmacist·2025

Related Experiment Video

Updated: Apr 20, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K

Antidiabetic medications and polypharmacy.

Emily P Peron1, Kelechi C Ogbonna2, Krista L Donohoe3

  • 1Geriatric Pharmacotherapy Program, Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University, Smith Building, Room 338, 410 North 12th Street, PO Box 980533, Richmond, VA 23298-0533, USA.

Clinics in Geriatric Medicine
|December 3, 2014
PubMed
Summary
This summary is machine-generated.

Polypharmacy, the use of multiple medications, poses risks for older adults, including poor adherence and adverse events. Careful consideration of antidiabetic drug risks and benefits is crucial for managing diabetes in this population.

Keywords:
Adverse drug eventsDiabetic complicationsGeriatric syndromesHypoglycemic agentsPolypharmacy

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.3K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Related Experiment Videos

Last Updated: Apr 20, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.3K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Area of Science:

  • Geriatric Medicine
  • Clinical Pharmacy
  • Endocrinology

Background:

  • Polypharmacy is a significant concern in older adults, linked to nonadherence, drug-drug interactions, drug-disease interactions, and adverse drug events.
  • Managing diabetes in older adults is complex due to high medication burden, chronic disease, and age-related physiological changes.

Purpose of the Study:

  • To highlight the challenges of managing diabetes in older adults with polypharmacy.
  • To emphasize the importance of understanding the risks and benefits of antidiabetic medications in this demographic.
  • To advocate for shared decision-making in diabetes care for older adults.

Main Methods:

  • This study is a review and synthesis of existing literature on polypharmacy and diabetes management in older adults.
  • Analysis of risks and benefits associated with common antidiabetic medications in the geriatric population.
  • Discussion of shared decision-making models for optimizing care.

Main Results:

  • Polypharmacy increases the risk of adverse outcomes in older adults with diabetes.
  • Older adults may have increased sensitivity to medications, necessitating careful drug selection.
  • Shared decision-making can improve medication adherence and patient outcomes.

Conclusions:

  • Providers must be aware of the specific risks and benefits of antidiabetic medications for older adults.
  • Implementing shared decision-making is essential for ensuring appropriate and safe diabetes care in this vulnerable population.
  • Optimizing medication regimens and fostering patient-provider collaboration are key to mitigating polypharmacy-related issues in older adults with diabetes.